{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:04:30Z","timestamp":1786122270143,"version":"build-2736575974"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Ethical Legal Implications of Psychedelics in Society"},{"name":"Ortus Foundation"},{"name":"Hollie Stenson Foundation"},{"DOI":"10.13039\/100007856","name":"Baylor College of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Psychedelics such as 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin are showing promising results in clinical trials for the treatment of mental health disorders, including post-traumatic stress disorder, addiction, and treatment-resistant depression. US Food and Drug Administration approval may be on the horizon. Yet, little is known about how these treatments will move from tightly controlled clinical trials to routine clinical care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study examines how psychedelic clinical investigators anticipate this transition and what challenges they expect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted semi-structured interviews with 21 clinical investigators based at major academic psychedelic research centers across the United States. We transcribed and analyzed these conversations using inductive and deductive coding to identify major themes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Investigators generally viewed psychedelic medicine as distinct from existing treatments, particularly in terms of drug effects, treatment models, and broader goals. They highlighted three major translational challenges: (i) uncertainty surrounding the role of psychotherapy, (ii) the cost of treatment and its scalability, and (iii) the effects of both hype and stigma on clinical uptake.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite these challenges, most investigators anticipated that psychedelic medicine could eventually fit into routine clinical care and may even improve it.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/tbm\/ibag027","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T11:38:33Z","timestamp":1776339513000},"source":"Crossref","is-referenced-by-count":1,"title":["From trials to clinics: investigators\u2019 perspectives on translating psychedelic research into clinical care"],"prefix":"10.1093","volume":"16","author":[{"given":"Joshua","family":"Mitchell","sequence":"first","affiliation":[{"name":"Ethical Legal Implications of Pyshcedelics in Society (ELIPSIS) Program, Center for Medical Ethics and Health Policy, Baylor College of Medicine , Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan","family":"Neitzke-Spruill","sequence":"additional","affiliation":[{"name":"Ethical Legal Implications of Pyshcedelics in Society (ELIPSIS) Program, Center for Medical Ethics and Health Policy, Baylor College of Medicine , Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S","family":"Mathai","sequence":"additional","affiliation":[{"name":"Ethical Legal Implications of Pyshcedelics in Society (ELIPSIS) Program, Center for Medical Ethics and Health Policy, Baylor College of Medicine , Houston, TX,","place":["USA"]},{"name":"The Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill O","family":"Robinson","sequence":"additional","affiliation":[{"name":"Ethical Legal Implications of Pyshcedelics in Society (ELIPSIS) Program, Center for Medical Ethics and Health Policy, Baylor College of Medicine , Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Kazan","sequence":"additional","affiliation":[{"name":"Ethical Legal Implications of Pyshcedelics in Society (ELIPSIS) Program, Center for Medical Ethics and Health Policy, Baylor College of Medicine , Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynnette A","family":"Averil","sequence":"additional","affiliation":[{"name":"Ethical Legal Implications of Pyshcedelics in Society (ELIPSIS) Program, Center for Medical Ethics and Health Policy, Baylor College of Medicine , Houston, TX,","place":["USA"]},{"name":"The Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX,","place":["USA"]},{"name":"The Menninger Clinic, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7819-519X","authenticated-orcid":false,"given":"Amy L","family":"McGuire","sequence":"additional","affiliation":[{"name":"Ethical Legal Implications of Pyshcedelics in Society (ELIPSIS) Program, Center for Medical Ethics and Health Policy, Baylor College of Medicine , Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"2026080705423087100_ibag027-B1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S2215-0366(24)00370-5","article-title":"Drug development in psychiatry: 50 years of failure and how to resuscitate it","volume":"12","author":"Nutt","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"2026080705423087100_ibag027-B2","doi-asserted-by":"crossref","first-page":"OT19037BR3","DOI":"10.4088\/JCP.OT19037BR3","article-title":"Inadequate response to treatment in major depressive disorder: augmentation and adjunctive strategies","volume":"81","author":"Rafeyan","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"2026080705423087100_ibag027-B3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41380-021-01200-3","article-title":"Treatment resistance in psychiatry: state of the art and new directions","volume":"27","author":"Howes","year":"2022","journal-title":"Mol Psychiatry"},{"key":"2026080705423087100_ibag027-B4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1057\/s41292-022-00294-4","article-title":"Psychedelic innovations and the crisis of psychopharmacology","volume":"19","author":"Langlitz","year":"2024","journal-title":"Biosocieties"},{"key":"2026080705423087100_ibag027-B5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1037\/pha0000084","article-title":"Clinical applications of hallucinogens: a review","volume":"24","author":"Garcia-Romeu","year":"2016","journal-title":"Exp Clin Psychopharmacol"},{"key":"2026080705423087100_ibag027-B6","volume-title":"The ASAM Principles of Addiction Medicine","author":"Yaden","year":"2024"},{"key":"2026080705423087100_ibag027-B7","author":"Hu","year":"2024"},{"key":"2026080705423087100_ibag027-B8","author":"Perrone","year":"2025"},{"key":"2026080705423087100_ibag027-B9","first-page":"439","article-title":"State drug laws","volume":"93","author":"Marks","year":"2024","journal-title":"Fordham Law Rev"},{"key":"2026080705423087100_ibag027-B10","doi-asserted-by":"crossref","first-page":"887255","DOI":"10.3389\/fpsyg.2022.887255","article-title":"Psychedelic-assisted psychotherapy\u2014a systematic review of associated psychological interventions","volume":"13","author":"Cavarra","year":"2022","journal-title":"Front Psychol"},{"key":"2026080705423087100_ibag027-B11","doi-asserted-by":"crossref","first-page":"2050324516683325","DOI":"10.1177\/2050324516683325","article-title":"Constructing drug effects: a history of set and setting","volume":"3","author":"Hartogsohn","year":"2017","journal-title":"Drug Sci Policy Law"},{"key":"2026080705423087100_ibag027-B12","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1177\/02698811251338214","article-title":"Set and setting of psychedelics for therapeutic use in psychiatry: a systematic review","volume":"39","author":"Estric","year":"2025","journal-title":"J Psychopharmacol (Oxf)"},{"key":"2026080705423087100_ibag027-B13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/15265161.2025.2434398","article-title":"Psychedelic medicine exceptionalism","volume":"25","author":"Cohen","year":"2025","journal-title":"Am J Bioeth"},{"key":"2026080705423087100_ibag027-B14","author":"Cheung"},{"key":"2026080705423087100_ibag027-B15","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/tbm\/ibae053","article-title":"Moving psychedelic-assisted therapies from promising research into routine clinical practice: lessons from the field of implementation science","volume":"14","author":"Adams","year":"2024","journal-title":"Transl Behav Med"},{"key":"2026080705423087100_ibag027-B16","doi-asserted-by":"crossref","first-page":"743599","DOI":"10.3389\/fpsyt.2021.743599","article-title":"The readiness of psychiatrists to implement psychedelic-assisted psychotherapy","volume":"12","author":"Page","year":"2021","journal-title":"Front Psychiatry"},{"key":"2026080705423087100_ibag027-B17","doi-asserted-by":"publisher","first-page":"104938","DOI":"10.1016\/j.drugpo.2025.104938","article-title":"Building standards of psychedelic care: qualitative examination of expert perspectives on safety, inclusion, and accountability","volume":"147","author":"Chwyl","year":"2026","journal-title":"Int J Drug Policy"},{"key":"2026080705423087100_ibag027-B18","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/1049732305276687","article-title":"Three approaches to qualitative content analysis","volume":"15","author":"Hsieh","year":"2005","journal-title":"Qual Health Res"},{"key":"2026080705423087100_ibag027-B19","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrn3530","article-title":"Effects of Schedule I drug laws on neuroscience research and treatment innovation","volume":"14","author":"Nutt","year":"2013","journal-title":"Nat Rev Neurosci"},{"key":"2026080705423087100_ibag027-B20","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/15265161.2024.2433436","article-title":"Embracing epistemic humility: rethinking psychedelic exceptionalism through diverse perspectives","volume":"25","author":"De Matas","year":"2025","journal-title":"Am J Bioeth"},{"key":"2026080705423087100_ibag027-B21","doi-asserted-by":"crossref","first-page":"1505894","DOI":"10.3389\/fpsyg.2025.1505894","article-title":"Psychedelics assisting therapy, or therapy assisting psychedelics? The importance of psychotherapy in psychedelic-assisted therapy","volume":"16","author":"Zamaria","year":"2025","journal-title":"Front Psychol"},{"key":"2026080705423087100_ibag027-B22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S2215-0366(23)00363-2","article-title":"Treatment with psychedelics is psychotherapy: beyond reductionism","volume":"11","author":"Gr\u00fcnder","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"2026080705423087100_ibag027-B23","author":"Glastra","year":"2023"},{"key":"2026080705423087100_ibag027-B24","doi-asserted-by":"crossref","first-page":"1025726","DOI":"10.3389\/fpsyt.2022.1025726","article-title":"The economics of psychedelic-assisted therapies: a research agenda","volume":"13","author":"Marseille","year":"2022","journal-title":"Front Psychiatry"},{"key":"2026080705423087100_ibag027-B25","doi-asserted-by":"crossref","first-page":"1293243","DOI":"10.3389\/fpsyt.2023.1293243","article-title":"Group psychedelic therapy: empirical estimates of cost-savings and improved access","volume":"14","author":"Marseille","year":"2023","journal-title":"Front Psychiatry"},{"key":"2026080705423087100_ibag027-B26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.61373\/pp024r.0025","article-title":"An estimate of the number of people with clinical depression eligible for psilocybin-assisted therapy in the United States","volume":"1","author":"Raib","year":"2025","journal-title":"Psychedelics"},{"key":"2026080705423087100_ibag027-B27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/02791072.2019.1593559","article-title":"Psychedelic-assisted group therapy: a systematic review","volume":"51","author":"Trope","year":"2019","journal-title":"J Psychoactive Drugs"},{"key":"2026080705423087100_ibag027-B28","year":"2022"},{"key":"2026080705423087100_ibag027-B29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1176\/appi.ajp.20230890","article-title":"Benefits and challenges of ultra-fast, short-acting psychedelics in the treatment of depression","volume":"182","author":"Ramaekers","year":"2025","journal-title":"Am J Psychiatry"},{"key":"2026080705423087100_ibag027-B30","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1089\/psymed.2023.0013","article-title":"Psychedelic commercialization: a wide-spanning overview of the emerging psychedelic industry","volume":"1","author":"Aday","year":"2023","journal-title":"Psychedelic Med (New Rochelle)"},{"key":"2026080705423087100_ibag027-B31","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jamapsychiatry.2022.2546","article-title":"Preparing for the bursting of the psychedelic hype bubble","volume":"79","author":"Yaden","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"2026080705423087100_ibag027-B32","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jamapsychiatry.2020.3672","article-title":"Psychedelics in psychiatry\u2014keeping the renaissance from going off the rails","volume":"78","author":"Yaden","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"2026080705423087100_ibag027-B33","doi-asserted-by":"crossref","first-page":"100967","DOI":"10.1016\/j.newideapsych.2022.100967","article-title":"The illusion of knowledge in the emerging field of psychedelic research","volume":"67","author":"Ona","year":"2022","journal-title":"New Ideas Psychol"},{"key":"2026080705423087100_ibag027-B34","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11673-024-10386-4","article-title":"History, hype, and responsible psychedelic medicine: a qualitative study of psychedelic researchers","volume":"22","author":"Barber","year":"2025","journal-title":"J Bioeth Inq"},{"key":"2026080705423087100_ibag027-B35","author":"Sevelius","year":"2017"},{"key":"2026080705423087100_ibag027-B36","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12888-018-1824-6","article-title":"Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature","volume":"18","author":"Michaels","year":"2018","journal-title":"BMC Psychiatry"},{"key":"2026080705423087100_ibag027-B37","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/09687637.2021.1897331","article-title":"Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment","volume":"28","author":"Thrul","year":"2021","journal-title":"Drugs Educ Prev Policy"},{"key":"2026080705423087100_ibag027-B38","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.socscimed.2012.03.018","article-title":"Cultural competence and evidence-based practice in mental health: epistemic communities and the politics of pluralism","volume":"75","author":"Kirmayer","year":"2012","journal-title":"Soc Sci Med"},{"key":"2026080705423087100_ibag027-B39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1556\/2054.2019.031","article-title":"The role of Indigenous knowledges in psychedelic science","volume":"4","author":"Fotiou","year":"2019","journal-title":"J Psychedelic Stud"},{"key":"2026080705423087100_ibag027-B40","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41386-023-01710-4","article-title":"Ensuring psychedelic treatments and research do not leave anyone behind","volume":"49","author":"Simon","year":"2024","journal-title":"Neuropsychopharmacology"}],"container-title":["Translational Behavioral Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/tbm\/article-pdf\/16\/1\/ibag027\/68332423\/ibag027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/tbm\/article-pdf\/16\/1\/ibag027\/68332423\/ibag027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T09:42:41Z","timestamp":1786095761000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/tbm\/article\/doi\/10.1093\/tbm\/ibag027\/8687164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/tbm\/ibag027","relation":{},"ISSN":["1613-9860"],"issn-type":[{"value":"1613-9860","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"ibag027"}}